Insights from a Multi-Country Survey: Healthcare Providers’ Perspectives on the Management of Adults with Neurofibromatosis Type 1 and Plexiform Neurofibroma
Open Access
- 8 October 2026
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- p. 1-25
Abstract
Introduction Neurofibromatosis type 1 (NF1) is a genetic, multi-system disorder characterized by a range of manifestations. Approximately 50% of patients with NF1 develop peripheral nerve sheath tumors [plexiform neurofibroma (PN)], which can cause substantial morbidity and often progress into adulthood. Historically, NF1-PN research has focused on pediatric patients; however, less is known in adult patients, in whom treatment options are also limited. This study aimed to provide insights into the management and treatment challenges in adults with NF1-PN from the perspective of healthcare providers (HCPs). Methods Two separate studies, one in the US and one across multiple countries (Canada, China, France, Germany, Japan, Italy, Spain, and the UK), were conducted with a mixed-methods, double-blinded design among HCPs who treat adults with NF1-PN. Qualitative interview data were collected to explore survey responses (US) or to inform quantitative study design (multi-country); quantitative data were collected through online surveys. Results Overall, 4 and 16 HCPs participated in the qualitative portion of the US and multi-country studies, whereas 41 and 124 HCPs participated in the quantitative portion, respectively. Physical examinations and radiologic imaging were used for diagnosis of NF1-PN across both studies, but family history was more frequent in the multi-country study (81–83% multi-country; 68–75% US). HCPs reported managing multiple high-burden manifestations, including brainstem or optic gliomas, hearing issues, neurocognitive or visual impairment, and neuropathic pain, resulting in patients missing an average of 6–8 days from school or work per month. Approximately 17–25% of patients drop out of care when transitioning from pediatric to adult care with lack of support/processes/guidelines noted as key challenges. Conclusion These results highlight unmet clinical needs in treatment of adults with NF1-PN worldwide; specifically, limited treatment options for PN growth and symptoms. HCPs identified need for better educational resources for patients and improved transition-of-care processes/resources.Keywords
Funding Information
- Alexion Pharmaceuticals
- Merck
This publication has 39 references indexed in Scilit:
- Clinical and Humanistic Burden Among Adults with Neurofibromatosis Type 1 and Symptomatic Plexiform Neurofibroma in the United StatesNeurology and Therapy, 2026
- The impact of insurance on adolescent transition to adult careHealth Care Transitions, 2025
- ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1eClinicalMedicine, 2023
- Neurofibromatosis‐associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort studyPediatric Blood & Cancer, 2019
- Emotional and behavioral problems in children and adolescents with neurofibromatosis type 1American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017
- Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1Ophthalmology, 2017
- Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social‐emotional functioning, and quality of lifeAmerican Journal of Medical Genetics Part A, 2015
- Healthcare transition in patients with rare genetic disorders with and without developmental disability: Neurofibromatosis 1 and williams–beuren syndromeAmerican Journal of Medical Genetics Part A, 2013
- Pediatric Plexiform Neurofibromas: Impact on Morbidity and Mortality in Neurofibromatosis Type 1The Journal of Pediatrics, 2012
- Management of Head and Neck Plexiform Neurofibromas in Pediatric Patients With Neurofibromatosis Type 1JAMA Otolaryngology–Head & Neck Surgery, 2005